{'52WeekChange': -0.1323908,
 'SandP52WeekChange': 0.0644362,
 'address1': '12340 El Camino Real',
 'address2': 'Suite 250',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.78,
 'askSize': 1000,
 'averageDailyVolume10Day': 930137,
 'averageVolume': 1563577,
 'averageVolume10days': 930137,
 'beta': 2.064985,
 'beta3Year': None,
 'bid': 6.59,
 'bidSize': 4000,
 'bookValue': 3.697,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 6.83,
 'dayLow': 6.6,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 221453024,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 7.2097144,
 'fiftyTwoWeekHigh': 8.87,
 'fiftyTwoWeekLow': 3.26,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 55889827,
 'forwardEps': -0.83,
 'forwardPE': -8.13253,
 'fromCurrency': None,
 'fullTimeEmployees': 17,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.10979,
 'heldPercentInstitutions': 0.56675,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/vikingtherapeutics.com',
 'longBusinessSummary': 'Viking Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'of novel therapies for metabolic and endocrine '
                        'disorders. Its lead drug candidate is VK2809, an '
                        'orally available tissue and receptor-subtype '
                        'selective agonist of the thyroid hormone receptor '
                        'beta, which is in Phase 2b clinical trials to treat '
                        'patients with biopsy-confirmed non-alcoholic '
                        "steatohepatitis. The company's lead drug candidate "
                        'also includes VK5211, an orally available '
                        'non-steroidal selective androgen receptor modulator '
                        'that is in Phase II clinical trials for the treatment '
                        'of patients recovering from non-elective hip fracture '
                        'surgery. It is also developing VK0612, an orally '
                        'available Phase 2b-ready drug candidate for type 2 '
                        'diabetes; and VK0214, an orally available tissue and '
                        'receptor-subtype selective agonist of the thyroid '
                        'hormone receptor beta for X-linked '
                        'adrenoleukodystrophy. Viking Therapeutics, Inc. was '
                        'founded in 2012 and is headquartered in San Diego, '
                        'California.',
 'longName': 'Viking Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 490025696,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_246791410',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -30542000,
 'nextFiscalYearEnd': 1640908800,
 'open': 6.75,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.28,
 'phone': '858 704 4660',
 'previousClose': 6.75,
 'priceHint': 2,
 'priceToBook': 1.8258047,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 6.83,
 'regularMarketDayLow': 6.6,
 'regularMarketOpen': 6.75,
 'regularMarketPreviousClose': 6.75,
 'regularMarketPrice': 6.75,
 'regularMarketVolume': 848462,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 72596400,
 'sharesPercentSharesOut': 0.16409999,
 'sharesShort': 11915564,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 11214389,
 'shortName': 'Viking Therapeutics, Inc.',
 'shortPercentOfFloat': 0.2123,
 'shortRatio': 7.52,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'VKTX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.424,
 'twoHundredDayAverage': 6.4247484,
 'volume': 848462,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.vikingtherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92130'}